H.C. Wainwright raised the firm’s price target on Wave Life Sciences to $22 from $15 and keeps a Buy rating on the shares. The WVE-N531 interim data today is “impressive when it comes to dystrophin expression levels, safety, and dosing, putting ‘N531 as a potential best-in-class exon skippers in the landscape,” the analyst tells investors in a research note. The firm says the mean absolute muscle content adjusted dystrophin expression of 9% is impressive across the landscape. The data follows a “considerably high” exon skipping activity, which validates Wave’s exon skipping platform and other pipeline programs, contends H.C. Wainwright. The firm increased its probability of sucess for WVE-N531 to 60% from 20%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences Reports Promising Duchenne Therapy Trial Results
- Wave Life Sciences announces interim data fom ogoing Phase 2 FORWARD-53 study
- Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
- Wave Life Sciences initiated with a Buy at B. Riley
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue